Evidence map›Paper›PMID 36952039›Full record

ReviewPediatric nephrology (Berlin, Germany)2023

What is circulating factor disease and how is it currently explained?

Samantha Hayward, Kevon Parmesar, Moin A Saleem

Open access · hybridAbstract readReview
In one paragraph

Review in Pediatric nephrology (Berlin, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Samantha HaywardTranslational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. Samantha.Hayward@nhs.net.ORCID http://orcid.org/0000-0002-3234-7549
Kevon ParmesarTranslational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0001-5222-6341
Moin A SaleemTranslational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.ORCID http://orcid.org/0000-0002-9808-4518
University of Bristol · GBNorth Bristol NHS Trust · GB

Funding

Medical Research Council MR/P024297/1Medical Research Council MR/R003017/1Medical Research Council MR/R013942/1Medical Research Council MR/W000105/1
6 · The paper itself

Abstract

Nephrotic syndrome (NS) consists of the clinical triad of hypoalbuminaemia, high levels of proteinuria and oedema, and describes a heterogeneous group of disease processes with different underlying drivers. The existence of circulating factor disease (CFD) as a driver of NS has been epitomised by a subset of patients who exhibit disease recurrence after transplantation, alongside laboratory work. Several circulating factors have been proposed and studied, broadly grouped into protease components such as soluble urokinase-type plasminogen activator (suPAR), hemopexin (Hx) and calcium/calmodulin-serine protease kinase (CASK), and other circulating proteases, and immune components such as TNF-α, CD40 and cardiotrophin-like cytokine-1 (CLC-1). While currently there is no definitive way of assessing risk of CFD pre-transplantation, promising work is emerging through the study of 'multi-omic' bioinformatic data from large national cohorts and biobanks.

Indexed as

Nephrotic SyndromeHumansProteinuriaReceptors, Urokinase Plasminogen ActivatorReceptors, Urokinase Plasminogen ActivatorCirculating factor diseaseNephrotic syndromeSteroid-resistant nephrotic syndromeSteroid sensitive nephrotic syndromeTransplant recurrence

Identifiers

PMID36952039
PMCPMC10514121
OpenAlexW4360600095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.